âåœãå±å
ã§ã®ãã¹ã¯ççšã«ã€ããŠãå人ã®å€æã«å§ãããæ¹éã瀺ããããšãåã次ã®ããã«è¿°ã¹ãŸããã(æµç°ç¥äºïŒ
ãå
šãçœçŽã§ã1人1人ã§èããŠäžãããšããã®ã¯åœãšããŠã®è²¬ä»»æŸæ£ã«è¿ããã®ã§ã¯ãªããã
ç§åŠçç¥èŠã«åºã¥ããŠåœãã¬ã€ãã©ã€ã³ã瀺ãã¹ãã ãšè©±ããŸããâ
ttps://www.fnn.jp/articles/-/482071
[å¿åãã]
?
Good!
?
Bad
ãã®å
ãã¹ã¯ççšçŸ©åã®ç·©åã§
ãã¹ã¯ãèªç±ã«ãªã£ããšããã§ããïŒ
ããããããåãã§å€ã人éãšããã®ã¯
ã³ããè¶çªã®äººé
ã³ããã¯ãã ã®é¢šéª
ã¯ã¯ãã³å±éº
ã³ããã¯ããããååšããªã
ã®äººéãªã®ã§ããããŸãã
[å¿åãã]
?
Good!
?
Bad
ã§ãåã¯ã¯ã®ä¿¡è
ãã¡ã¯æé ãããã€ããæãã ãšæã蟌ãã§æµ
ã¯ããªåŠèšã
å°é家ã«æ¯ãåããæ£æ°ã§ã¯ãªãã
[å¿åãã]
?
Good!
?
Bad
ãŸããåœç¶ããã
ãJNNäžè«èª¿æ»ãå
é£æ¯æç35.5%ãå
æãã1.9ãã€ã³ãäžèœãäžæ¯æçã62.2%ã§æ¿æš©çºè¶³åŸéå»æé«ïœ2023.2.5
ttps://newsdig.tbs.co.jp/articles/-/313041?display=1
[å¿åãã]
?
Good!
?
Bad
ç岡ãŸãã NHKå
å
«çååžè°äŒè°å¡åè£äºå®è
@NaoKi39340431·2æ3æ¥
åæ¿å
åæå±±æ¯éšé·ã®æå
æ¿åããã®å€§èª¿åæ³¢å米買ãããšæã£ãŠãã£ããã«å
¥ã£ãŠããã®ã§ãããªãã ãçµæ§é«ããããåãããªãâŠ
3äžåäœã¯èŠæããŠããŸãããæäœéé¡30äžåããã¯æãåºããªãð¥
æé«éé¡360äžåãªã®ã§ããããã¯äžäœäœã売ãããŠããã®ãåããæ¹ããã£ããããŸããïŒ
[å¿åãã]
?
Good!
?
Bad
幎å¯ãçžæã®ãªã¬ãªã¬è©æ¬ºãããã§ããæå£ã§é£ãããšããã
ãªãã ã倧調åæ³¢åç±³ã£ãŠïœ
[å¿åãã]
?
Good!
?
Bad
売ã£ãŠãã ããè²·ã£ãŠããã«ããããããããªã
åæã
[å¿åãã]
?
Good!
?
Bad
壷ã¯è²·ã£ãã®ïŒãããªéãªãïŒ
[å¿åãã]
?
Good!
?
Bad
åœå
ã§ã¯ïŒæ¥ãæ°åã³ãããŠã€ã«ã¹ææè
ãæ°ãã«ïŒäžïŒïŒïŒïŒäººç¢ºèªãããã
1æ¥ãããã®ææè
ãïŒäžäººãäžåãã®ã¯æšå¹ŽïŒïŒæïŒïŒæ¥ä»¥æ¥ã
ããªãæžã£ãŠæ¥ãŸããã
[å¿åãã]
?
Good!
?
Bad
BQãæã£ãã»ã©äŒžã³ãŠãªããBNã®æ¹ãå°ãã ã䌞ã³ãŠã
2é£ç¶ã®BA.5æ³¢ã§äžæçãªææå
ç«ãæç«ããã®ããªãããšéœäŒã¯äººæµãå°ãªã
[å¿åãã]
?
Good!
?
Bad
壺çã«ã¯ãã¹ã¯çãããšææãæ¡ãããã ãïŒ
æžã£ãŠããŠãããã
ããã£ãŠãã£ã±ãåå
«çŸã ã£ããã ãª
[å¿åãã]
?
Good!
?
Bad
Sukuna@SukunaBikona7·1å
ã€ã³ããã·ã¢ã§ã¯XBB.1.5ãè¿œãæããXBB.1.9.1ã50%ãè¶
ããå²åã«ã
ã·ã³ã¬ããŒã«ãã€ã®ãªã¹ã§ãå¢å åŸåã
ã¢ãžã¢ããšãŒãããã§ã¯XBB.1.5以äžã®æé·åªäœæ§ããããããšã
ãã ã»ãŠã§ã³ã»ã©ãŒãº(TWenseleers)
ã€ã³ããã·ã¢ã§ã¯ãOmicron XBB.1.9.1ïŒé»è²ïŒã®ã·ã§ã¢ã50%ãè¶
ããŸãããããã¯Omicron XBB.1.5ã®æ³¢ïŒã·ã¢ã³ïŒãã¹ãããããåœã®äžã€ã§ãããã§åªäœæ§ããªãã£ãããã§ã¯ãªããããã«é©ããå¥ã®ããªãšãŒã·ã§ã³ãåºçŸããããã§ãã2çªç®ã¯ã·ã³ã¬ããŒã«ã§ãXBB.1.9.1ã15ïŒ
ã®ã·ã§ã¢ãå ããŠããŸãã
[å¿åãã]
?
Good!
?
Bad
Sukuna
@SukunaBikona7
ã€ã³ããã·ã¢ã§ã¯XBB.1.5ãè¿œãæããXBB.1.9.1ã50%ãè¶
ããå²åã«ã
ã·ã³ã¬ããŒã«ãã€ã®ãªã¹ã§ãå¢å åŸåã
ã¢ãžã¢ããšãŒãããã§ã¯XBB.1.5以äžã®æé·åªäœæ§ããããããšã
åŒçšãã€ãŒã
Tom Wenseleers
@TWenseleers
·
55å
In Indonesia, Omicron XBB.1.9.1 (yellow) now has a >50% share - one country at least that will skip an Omicron XBB.1.5 wave (cyan) - not because it didn't have an advantage there, but because another even fitter variant emerged. Second is Singapore, where XBB.1.9.1 has 15% share.
ã€ã³ããã·ã¢ã§ã¯ãOmicron XBB.1.9.1 (é»è²) ãçŸåš> 50% ã®ã·ã§ã¢ãå ããŠããŸã - å°ãªããšã 1 ã€ã®åœã Omicron XBB.1.5 ãŠã§ãŒã (ã·ã¢ã³) ãé£ã°ããŸã - ããã«åªäœæ§ããªãã£ãããã§ã¯ãªããããããå¥ã®ããã«é©åãªããªã¢ã³ããåºçŸããããã§ãã 2 çªç®ã¯ã·ã³ã¬ããŒã«ã§ãXBB.1.9.1 ã®ã·ã§ã¢ã¯ 15% ã§ãã
[å¿åãã]
?
Good!
?
Bad
Tom Wenseleers
@TWenseleers
Here the inferred growth advantage of XBB.1.9.1 & XBB.1.5 over BQ.1.1*. XBB.1.9.1 ahead of the pack. It has identical spike than XBB.1.5 (convergently evolved), but 2 fitness enhancing amino acid changes in ORF1a & 1 AA change in ORF9b. Code at ttps://github.com/tomwenseleers/LineageExplorer/blob/main/global%20analysis.R
ããã§ã¯ãBQ.1.1 *. XBB.1.9.1 ã«å¯Ÿãã XBB.1.9.1 ãš XBB.1.5 ã®æšå®æé·çã矀ãæããŠããŸãã XBB.1.5 (åæé²å) ãšåãã¹ãã€ã¯ããããŸãããORF1a ã® 2 ã€ã®ãã£ãããã¹åŒ·åã¢ããé
žã®å€åãš ORF9b ã® 1 ã€ã® AA ã®å€åããããŸãã
[å¿åãã]
?
Good!
?
Bad
Tom Wenseleers
@TWenseleers
Given that spike of XBB.1.9.1 is the same as that of XBB.1.5* it should occupy the same immunity niche though... Except for spreading slightly faster, it could therefore be roughly taken as equivalent to XBB.1.5 in terms of consequences.
XBB.1.9.1 ã®ã¹ãã€ã¯ã XBB.1.5* ã®ã¹ãã€ã¯ãšåãã§ããããšãèãããšãåãå
ç«ããããå ããã¯ãã§ã... æ¡æ£ããããã«éãããšãé€ãã°ãXBB.1.5 ãšã»ãŒåçãšèŠãªãããšãã§ããŸãã
[å¿åãã]
?
Good!
?
Bad
Tom Wenseleers
@TWenseleers
Here growth in cases by different variants, including XBB.1.9.1, in Indonesia, as estimated by
@MoritzGerstung
... ttps://nbviewer.org/github/gerstung-lab/SARS-CoV-2-International/blob/main/genom
icsurveillance-int.ipynb#Check-some-fast-growing-lineages
ããã§ã¯ã
@MoritzGerstung
... ttps://nbviewer.org/github/gerstung-lab/SARS-CoV-2-International/blob/main/genom
icsurveillance-int.ipynb#Check-some-fast-growing-lineages
ã§æšå®ããããã€ã³ããã·ã¢ã«ããã XBB.1.9.1 ãå«ãããŸããŸãªäºçš®ã«ããçäŸã®å¢å ã瀺ããŸãã
[å¿åãã]
?
Good!
?
Bad
Angama
@Angama_Market
ãçµæžã«ç Žæ»
çãªã€ã³ãã¯ããªã®ã§ã¯ã
ã¢ã¡ãªã«ã§ã¯çŸåšãŸã§ã«
ã»çŽ3600äžäººãã³ãããŠã€ã«ã¹é·æé害
ã»ææè
ã®çŽ30ïŒ
ãé·æé害
ã»ãã®ãã¡ã®çŽ40ïŒ
ãæ¥åžžç掻ã«ãæ¯é
ïŒâã€ãŸãææè
ã®12ïŒ
ãæ¥åžžç掻ã«æ¯éããããããã«ãªãïŒ
ãšããèšäºã
COVID-36ã®æ€æ»ã§éœæ§ãšãªã£ãçŽ19,40äžäººã®ã¢ã¡ãªã«äººãããã·ã·ããå·ã®<>%以äžãå«ããé·ãCOVIDçç¶ããããšå ±åããŠããŸããttps://twitter.com/Angama_Market/status/1622596063130447876
[å¿åãã]
?
Good!
?
Bad
ãããã¯ã©ãŒã±ã³ãå¹ãé£ã°ããããšã¯ãªãåŒã ãã©ïŒç¬
[å¿åãã]
?
Good!
?
Bad
Ré£ç¶äœ MT Ph.D D.H.Sc.
@Rrenzokutai
æ¥ã«æ¥ã第9æ³¢ã¯ããã¹ãŠã®å Žæã§ãã¯ã©ã¹ã¿ãŒã ãããã«ãªãã§ããããã
ãããèªåãå®ãäºããã§ããªããªããŸãã
åŒçšãã€ãŒã
ç¹æ»ééQ-TEAM
@QBK_jitensya
R032(1人ã32人ã«ææããã)ãšèšãããXBB.1.5
BA.5(R022)ã®1.5å
麻ç¹ãR020ããã
å
¥ãæ¿ããæã ãšæã£ãŠããæ¢ã«ç«ã¡äžãã£ãŠãªãïŒ
ããŒã¿ã1/23ïœ1/29ãªã®ã§ãã£ãšå¢ããŠãããºâŠ
ç±³åœã¯ãã¹ã¯æšå¥šã«åãæ¿ãã
æ¥æ¬æ¿åºã®ãã¹ã¯æšå¥šãããããããã¹ã¯å€ãã®å¥œæ©ããšæããŠã人ã¯ã€ãããšæã
ttps://twitter.com/QBK_jitensya/status/1622380712384172032
[å¿åãã]
?
Good!
?
Bad
NCCCM
@Ecccm2Ecccm
ïŒææããæã«ã¯ææããã
ãªãæ°ãéãæ¯èŒããªãã®ããã§ããªãã®ãã
ã¯ã¯ãã³ãæã€ãš
éçãæžã
æ»äº¡ãæžã
åŸéºçãæžã
äžå¹žã®ç·åãæžããããã«æå¹ãªã®ã«ããææããæã«ã¯ææãããã¿ãããª1ã0ãã®ããžã¿ã«æèãæã¡åºããªãã§æ¬²ããã
[å¿åãã]
?
Good!
?
Bad
ããªãžã£ã³
ç±³åœã«ããã1ææçµé±ã®æ»å ã®11%ã¯ã#Covid19ã#fluã#pneumoniaã«ãããã®ã§ããã
ã»ãšãã©ã®å Žåã#Covidã¯èšºææžã«åºç€çãªæ»å ãŸãã¯å¯äžããæ»å ãšããŠèšèŒãããŠããŸããã
[å¿åãã]
?
Good!
?
Bad
ð°ãã§ïœºïœ²ïŸð
@KDMCYcpefGyBUq7
æè¿ã®Roã¯ç¥ããªãã£ããã©30ãªããŠæ°åã«ãªã£ãŠãã®ããBA5ã®ãšãã§18.6ãããã ã£ãããªããã ãå
ç«ããªãéå£ã§ããšããRoã®å®çŸ©ã§ã¯éº»ç¹äžŠã¿ã®ææåã¯èšãéãã§ã¯ãªãããšãèšãããŠãã
åŒçšãã€ãŒã
ãããŒ@空æ°ææ察çå®æœäž
@medical_for_all
空æ°ææãšãªããšçµæ žã麻ç¹ãæãæµ®ãã¹ãŸãã1人ã®æ£è
ãããäœäººã®äººã«ãã€ãããšããåºæ¬åçç£æ°ïŒR0ïŒã§èããŸã
ã€ã³ãã«ãšã³ã¶:R0ïŒ2
é³¥ã€ã³ãã«ãšã³ã¶ïŒH7N9ïŒ: R0ïŒ0.37
çµæ ž:R0ïŒ5
麻ç¹: R0ïŒ15ã22
æ°åã³ãããªãã¯ãã³æ ªä»¥é: R0ïŒ22ã
æ°åã³ããïŒXBB.1.5ïŒ: R0ïŒ30ã
[å¿åãã]
?
Good!
?
Bad
ã³ããæ»Ã3ååŸããïŒè¶
éæ»äº¡è
æ°ã ããããã¯ãæ»äº¡çã1.3åçšåºŠã«ãªã
[å¿åãã]
?
Good!
?
Bad
é³¥ã€ã³ãã«ã人ãžã®ææ240人ãšãèŠããããªæ°ããã
[å¿åãã]
?
Good!
?
Bad
ð°ãã§ïœºïœ²ïŸð
@KDMCYcpefGyBUq7
ãã 2ã¶æã»ã©ã§9å人ãšèšãããäžåœã§ã®åãŸããææè
å¢å ãèããããææåã¯ããã«äžãã£ãŠãŠä»ã§ã¯éº»ç¹ãè¶
ããŠãã®ãããããªãã
åŒçšãã€ãŒã
st@å
¬è¡è¡çã»ç«åŠææ
@styh131582
R0ãšããã®ã¯ãå
ç«ããªãéå£ã§ã1人ã®ææè
ãå¹³åããŠäœäººææãããããšããææšã§ãã
ãããããªãã¯ãã³ãæµè¡ããæç¹ã§ã¯ãã§ã«ã¯ã¯ãã³ããã«ã¿ãŸã§ã«ããææã§å
ç«ãæã€äººãå€ãã£ãã§ãã
[å¿åãã]
?
Good!
?
Bad
ããã
Offsideð»@yfuruse·2æé
H5N1ã®ããææäŸã¯240ãšãªããCFRã¯56ïŒ
åŒçšãã€ãŒã
Xabier Ostale (xabitron1@mastodon.social)@xabitron1·7æé
"As of 5 Jan 2023, a total of 240 cases of human infection with avian influenza A(H5N1) virus have been reported from four countries within the Western Pacific Region since January 2003 (Table 1). Of these cases, 135 were fatal, resulting in a case fatality rate (CFR) of 56%."
[å¿åãã]
?
Good!
?
Bad
ããšæšæ¥ã®ã¹ãŠã§ãŒãã³ã®è©±ããããã¯æ°ã«ãªããç»å蚺æå»Kããã®èšç®ã§ã¯ãªããŠ
ããã¯çŸå°ã®å»åž«ã®èšãCFRã ãã
Offsideð»@yfuruse·2æ5æ¥
ã¹ãŠã§ãŒãã³ã®ãã®æ°å
ãã€ã³ãã«ããèŽæ»çäœãããšããã®ã©ããªããšãèšã£ãŠããæ¥æ¬ã®äžéšã®å°é家ã«è§£èª¬ãããŠãããããã
CFRã1幎åã®0.13ïŒ
ãã3.2ïŒ
ã«ããã£ãŠãã
ïŒCFR: Case Fatality Ratio. çäŸèŽæ»çïŒ
åŒçšãã€ãŒã
John Hess MD@DrJohnHhess·2æ4æ¥
Lack of COVID attenuation?
Look what is happening in Sweden. The week of 1/24/22 had 284,000 cases. Week of 2/14/22 there were 358 deaths. CFR of 0.13%. The week of 12/29/22 there were 12,972 cases. Week of 1/2/23 415 deaths. CFR 3.2%. That is a 24 fold INCREASE!
ð§µ
[å¿åãã]
?
Good!
?
Bad
æ»äº¡ç3.2ïŒ
ã£ãŠã®ã¯éåžžã«å€§ããªæ°åã§ããã ã®é¢šéªæŽŸããå¹ãé£ã¶æ°å
ããïŒãã¶ãXBFïŒãåŸåŒã®XBB.1.9.1ãå¹ãé£ã°ããŠãããã幞ã
[å¿åãã]
?
Good!
?
Bad
æšæ¥èšã£ãŠããã«ã¿ã®èšŒãæã€XBB.1ïŒ486PïŒ681Pãªãããå¹ãé£ã°ã
[å¿åãã]
?
Good!
?
Bad
ãã¹ã¯çŸ©åã»ãŒè§£é€ããïŒé±éã倧å€æ°ã®åžæ°ãå€ããææè
æžïŒéåœ
ttps://jp.yna.co.kr/view/AJP20230206003300882?section=society-culture/index
ããœãŠã«è¯åãã¥ãŒã¹ãéåœã®äžå€®é²ç«å¯Ÿçæ¬éšã«ãããšãïŒæ¥ååïŒæãŸã§ã®ïŒïŒæéã«åœå
ã§æ°ãã«ç¢ºèªãããææè
ã¯ïŒïŒïŒïŒäººã§ãæšå¹ŽïŒæïŒïŒæ¥ïŒïŒïŒïŒïŒäººïŒä»¥æ¥çŽïŒã«æåã¶ãã®äœæ°Žæºãšãªã£ããå±å
ã§ã®ãã¹ã¯ççšçŸ©åãç·©åãããïŒæïŒïŒæ¥ããïŒé±ééããã«ããããããæ°èŠææè
æ°ãæžãç¶ããŠããã®ã¯ãç·©ååŸããã¹ã¯ççšãç¶ãã人ãå€ããããšã¿ãããŠãããä»åŸãææè
æ°ã®æžå°ãç¶ãèŠéãã ã
ïŒæïŒïŒæ¥ããå»çæ©é¢ãå
Œ
±äº€éæ©é¢ãªã©ãé€ãå±å
ã§ã®ãã¹ã¯ççšçŸ©åã解é€ãããæœäŒæéãªã©ãèžãŸãããšçŽïŒé±éåŸã«ã¯ææè
ãäžæçã«å¢ããå¯èœæ§ããããšææãããŠããããã¯ã£ãããšããæžå°åŸåã瀺ãããã
ãã®ãããªçµæã«é¢é£ããéé¡ç¢©ïŒãã§ã³ã»ã®ãœã¯ïŒæ°åã³ãããŠã€ã«ã¹ç¹å¥å¯Ÿå¿å£é·ïŒåœå®¶ææçå±æ©å¯Ÿå¿è«®åå§å¡é·ïŒã¯ãã®æ¥ã®å®äŸèšè
äŒèŠã§ãæ確ãªæžå°åŸåãèŠæ¥µããäžã§ãã¹ã¯ççšçŸ©åãç·©åãããšãããã¹ã¯æªççšã«ãã£ãŠææè
ãå¢å ããŠããæžå°ããŒã¹ããããäžåãå¯èœæ§ããããšææããã
ãŸãççšçŸ©åãç·©åãããŠããççšãç¶ããŠãã人ãå€ããããç·©åã®åœ±é¿ãããã«ç¢ºèªããã®ã¯é£ãããšã®èãã瀺ããã
ã»ãšãã©ã®å Žæã§ãã¹ã¯ççšçŸ©åã解é€ããããã®ã®ãå±å
ã ãã§ãªãå±å€ã§ããã¹ã¯ççšãç¶ããŠãã人ã¯äŸç¶ãšããŠå€ãã
ãã éæ°ã¯ãã¹ã¯ãå€ã人ãå¢ããã°ææè
ãå¢å ããã®ã¯é¿ããããªããšããéçåãªã¹ã¯ã®é«ã人ã¯ãªãã¯ãã³æ ªã«å¯Ÿå¿ããæ¹è¯ã¯ã¯ãã³ã®æ¥çš®ãéèŠãšåŒ·èª¿ããã
[å¿åãã]
?
Good!
?
Bad
äžæ¹ãäžåœããã®å
¥åœè
ã®ææçãäœãç¶æãããŠããããšã«ã€ããŠã¯è©äŸ¡ãã€ã€ããäžåœã®ææç¶æ³ãåæ ããããã®ã§ã¯ãªããšãããäžåœå
ã®ææè
æ°ã倧å¹
ã«æžã£ããšèããããææè
ãéçè
æ°ãæ»äº¡è
æ°ã®ãããªïŒå
¬åŒã®ïŒæ°åãèŠããããšè¿°ã¹ãã
yugiri@yna.co.kr
[å¿åãã]
?
Good!
?
Bad
ãã«ã¿ã匷æ¯ã ã£ãã®ã¯ããªã³åæéšäœã綺éºã«è£ããŠNSPïŒãšããé¢ä¿ããã®ã ãããã©
ããããã®çš®åç匟ã®é
眮ãè¯ãã£ãæš¡æ§
[å¿åãã]
?
Good!
?
Bad
现èèåã®æã«ã³ããã¯è£ãããã ãããããŠçš®åç匟ãæäžãã
ãããäžæãåããŠããããã
[å¿åãã]
?
Good!
?
Bad
æ¯æ§ãèšãå Žåã®ã³ãŠã¢ãªæ¯ã®Eã¿ã³ãã¯ã«å€åã¯ãªã
å¹çãšãæ©èœã®åé¡ãïŒç
åæ§ã®é«ã
ã ããACE2å容äœãšã®çµåå匷åã¯ç
åæ§ãäžããåå ã«ããªã
[å¿åãã]
?
Good!
?
Bad
ãã®ææã¯æ¥æ¬ã§ãããã ãã©ããã¹ã¯ã¯äžåœããã®pm2.5ã
ç¹ã«éåœã®ãã¹ã¯ã¯ãã®ããã«éçºããããã
[å¿åãã]
?
Good!
?
Bad
ã ããXBB.1.5ãªãªãžãã«ãå
¥é¢çãäžããªããšããã®ã¯æå ±ã§ãããšåæã«ãã³ã°ã³ãããã¯æªåã®äºæãããªã
[å¿åãã]
?
Good!
?
Bad
ãããŠåããææãããŠãããXBB.1.5ã¯ãã1ã©ã³ã¯æ§èœãäžãããããã¡ããã
[å¿åãã]
?
Good!
?
Bad
Ré£ç¶äœ MT Ph.D D.H.Sc.
@Rrenzokutai
ã»ãããŸãé ããŠããããæ²çžçã
åŒçšãã€ãŒã
Masami Kawamurað§ââïžPh.D, IPP Okinawa
@sirenamel
çãâå»å¹ŽïŒïŒä»£ä»¥äžã®ïŒäººãæ°åã³ããææã§æ»äº¡âãšå
¬è¡šïœNHK æ²çžçã®ãã¥ãŒã¹ ttps://www3.nhk.or.jp/lnews/okinawa/20230206/5090021865.html
ç§ãé瀺è«æ±ãããããããªãèšè
äŒèŠããŠçºè¡šããæ²çžçð€·ââïž
@Rrenzokutai @genka97
[å¿åãã]
?
Good!
?
Bad
Offsideð»
@yfuruse
äžåœã¯å
¥è©Šã®äœè²ã§ã
é·è·é¢èµ°ãããããåã©ããã¡ãæ°åã³ããã«ææãã圱é¿ãæ®ã£ãŠãããšèããããã ã
æ¥æ¬ãããã£ãšïŒãã®é¢ã§ã¯ïŒé²ãã§ããã
åŒçšãã€ãŒã
Jess
@MeetJess
Multiple places in Southwest China's Guizhou Province decided to cancel long-distance running requirements, part of the PE exam, for the high school entrance examinations this year, considering the impact that COVID-19 might still leave on students' health ttps://globaltimes.cn/page/202302/1284904.shtml
äžåœå西éšã®è²Žå·çã®è€æ°ã®å Žæã§ã¯ãCOVID-19 ãåŠçã®å¥åº·ã«äŸç¶ãšããŠåœ±é¿ãäžããå¯èœæ§ãããããšãèæ
®ããŠãä»å¹Žã®é«æ ¡å
¥è©Šã®äœè²è©Šéšã®äžéšã§ããé·è·é¢èµ°ã®èŠä»¶ããã£ã³ã»ã«ããããšã決å®ããŸããã
貎å·çã®é«æ ¡ã¯ãCOVIDã®å¥åº·ãžã®åœ±é¿ãæããŠé·è·é¢èµ°ã®ãã¹ããäžæåæ¢ããŸã
ç°çæå ±
å
¬éæ¥: Feb 06, 2023 01:21 PM
ttps://www.globaltimes.cn/page/202302/1284904.shtml
[å¿åãã]
?
Good!
?
Bad
Jess
@MeetJess
âExperts have reminded that strenuous exercises should be avoided after people recover from COVID-19, so as to prevent recurrent illness, or aggravating heart damage after viral infection, according to media reportsâ
ãã¡ãã£ã¢ã®å ±éã«ãããšãå°é家ã¯ã人ã
ãCOVID-19ããå埩ããåŸãç
æ°ã®åçºããŸãã¯ãŠã€ã«ã¹ææåŸã®å¿èã®æå·ã®æªåãé²ãããã«ãæ¿ããéåãé¿ããã¹ãã§ããããšãæãåºããŸãããã
[å¿åãã]
?
Good!
?
Bad
ãªãããã
æ¥æ¬ä»¥å€ã®è«žå€åœã®æ¹ãããã£ãœã©ã¡ãããšããŠãããã
[å¿åãã]
?
Good!
?
Bad
ç»å蚺æå»kðŸå±ä»£éŠçµµ@AdultSpotDiffer·7å
ãã«ã¬ãªã¢ã§ã¯äººå£æ¯ã§æ¥æ¬ã®10å以äžäº¡ããªãããŠããã®ã§ãCOVID-19ã«å¯ŸããŠè匱ãªæ¹ã¯æ¢ã«äº¡ããªãããŠããããããã°ããã¯æ»è
ãå¢ãã«ãããæ£è§£ãªæ°ãããŸãã
åŒçšãã€ãŒã
ãªãã@naok8686·42å
è¿ä¿¡å
: @AdultSpotDifferãã
ãã«ã¬ãªã¢ã¯çŽè¿ã®å幎ããããèŠããšã»ãšãã©ã¯ã¯ãã³æã£ãŠãªãã®ã«æ»è
ãã»ãšãã©å¢ããŠãªãã
ã¯ã¯ãã³ãæããªããšæ»è
ãå¢ããã¯ããªã®ã«ãªããªã®ãïŒïŒ
ã¯ã¯ãã³æããªããŠãèªç¶å
ç«ãååæ©èœãããšããããšãã
[å¿åãã]
?
Good!
?
Bad
äžææ話é¡ã«ãªã£ãã¢ã¬ã
ç®±æ ¹é§
äŒã§ç·ååªåããé§æŸ€å€§åŠã®ç°æŸ€éžæã¯ã³ããææã§çŽ1é±éæ©ãããšããã§ããã60%ã®ç¶æ
ã ã£ã
ttps://rikujyokyogi.co.jp/archives/90360
[å¿åãã]
?
Good!
?
Bad
ããã§ãæ»è
ãå€ãã¹ãŠã§ãŒãã³
[å¿åãã]
?
Good!
?
Bad
ã¢ãŒãªããã»ã²ã«ã·ã¥ãã¥ã³ã°
è¿ä¿¡å
TWenseleersãã
ã¯ããBA.1.9.1ãæåŸã®ã¢ãã«ã©ã³ã§ç§ã®æ³šæãåŒããŸãããæ±åã¢ãžã¢ã§éåžžã«ããèŠãããŸãã
XBB.1.5ãšåãS:F486På€ç°äœã§ããã2ã€ã®orf1å€ç°ïŒãã®æ矩ã¯äžæïŒã«ããå®çŸ©ããã1.9ããã¯ã°ã©ã³ãã«ãããŸãã
[å¿åãã]
?
Good!
?
Bad